Related Experiment Video
Updated: Apr 15, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
The genetic landscape of diffuse large B-cell lymphoma
Laura Pasqualucci1, Riccardo Dalla-Favera2
1Associate Professor of Pathology and Cell Biology, Institute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, NY.
Genomic studies have transformed the understanding of Diffuse large B-cell lymphoma (DLBCL), revealing genetic alterations that drive this cancer. This research identifies new diagnostic markers and therapeutic targets for improving patient outcomes.
Area of Science:
- Genomics
- Molecular Biology
- Hematology
- Oncology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a prevalent and aggressive lymphoid malignancy with a significant proportion of patients remaining incurable.
- Advances in genome-wide sequencing technologies have significantly enhanced our comprehension of the genetic underpinnings of DLBCL.
- Genetic alterations in DLBCL are crucial for tumor initiation, expansion, and can influence treatment efficacy.
Purpose of the Study:
- To review recent progress in the genomic characterization of Diffuse large B-cell lymphoma.
- To discuss how genomic insights have illuminated DLBCL biology.
- To identify potential prognostic and therapeutic targets based on genetic findings.
Main Methods:
- Comprehensive analysis of genomic and transcriptional changes in DLBCL.
- Review of recent sequencing technologies and their application to DLBCL research.
- Integration of genetic findings with clinical outcomes and therapeutic strategies.
Main Results:
- Identification of previously unrecognized alterations in key cellular pathways critical to DLBCL.
- Discovery of genetic lesions that correlate with patient diagnosis, risk stratification, and treatment response.
- Uncovering of novel genetic targets for potential therapeutic intervention in DLBCL.
Conclusions:
- Genomic characterization has provided profound insights into DLBCL biology, moving beyond traditional understanding.
- Newly identified genetic alterations hold promise as biomarkers for improved diagnosis and risk assessment.
- Emerging genetic targets are actively being explored in clinical trials for novel DLBCL therapies.
More Related Videos
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
08:53Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Related Concept Videos
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...